Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunosuppressive drug therapy

W J McCune1, D K Vallance, J P Lynch

  • 1Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0358.

Current Opinion in Rheumatology
|May 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The devil's in the dosing: severe drug-induced liver injury in a hydroxychloroquine-naive patient with subacute cutaneous lupus erythematosus and porphyria cutanea tarda.

Lupus·2018
Same author

The ratio of erythrocyte sedimentation rate to C-reactive protein is useful in distinguishing infection from flare in systemic lupus erythematosus patients presenting with fever.

Lupus·2018
Same author

The Prognostic Importance of Bronchoalveolar Lavage Fluid CXCL9 During Minimal Acute Rejection on the Risk of Chronic Lung Allograft Dysfunction.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis.

Clinical and experimental immunology·2017
Same author

Impact of Allograft Injury Time of Onset on the Development of Chronic Lung Allograft Dysfunction After Lung Transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

Impact of axial root growth angles on nitrogen acquisition in maize depends on environmental conditions.

Annals of botany·2016

Immunosuppressive drugs like azathioprine and cyclophosphamide may offer a survival benefit for interstitial lung disease in rheumatic disorders when added to prednisone. However, more controlled studies are needed to confirm efficacy.

Area of Science:

  • Rheumatology
  • Pulmonology
  • Pharmacology

Background:

  • Interstitial lung disease (ILD) is a common complication of rheumatic disorders, including polymyositis-dermatomyositis, rheumatoid arthritis, systemic sclerosis, and mixed connective tissue disease.
  • Current treatment strategies for chronic interstitial pneumonitis-fibrosis in these patients often involve immunosuppressive-cytotoxic agents.

Purpose of the Study:

  • To review existing data on the efficacy of azathioprine, cyclophosphamide, chlorambucil, cyclosporine, and methotrexate in managing chronic interstitial pneumonitis-fibrosis associated with rheumatic diseases.
  • To assess the comparative effectiveness of these agents against corticosteroid monotherapy.

Main Methods:

  • Literature review of anecdotal successes and small, uncontrolled case series.
  • Analysis of studies evaluating immunosuppressive agents in conjunction with or as alternatives to corticosteroids.

Related Experiment Videos

Main Results:

  • Limited evidence suggests azathioprine or cyclophosphamide, when added to prednisone, may provide a slight long-term survival advantage in ILD.
  • Cyclosporine use has shown less encouraging results.
  • Data for chlorambucil and methotrexate are insufficient for drawing conclusions.

Conclusions:

  • While current data are largely anecdotal and uncontrolled, azathioprine and cyclophosphamide show potential benefit in combination with prednisone for rheumatic ILD.
  • Further rigorous, controlled clinical trials are essential to definitively establish the role and optimal use of these immunosuppressive agents in treating interstitial lung disease.